Ocular Disease

Results of study show potential of RNAi therapeutics for ocular diseases

Published in Biotech Business Week, January 10th, 2005

Alnylam Pharmaceuticals, Inc., (ALNY), a therapeutic RNA interference (RNAi) company, presented data from in vitro and in vivo studies on using RNAi to silence expression of Vascular Endothelial Growth Factor (VEGF), a key mediator of angiogenesis in ocular diseases.

The abnormal over-expression of VEGF is linked to ocular neovascular diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy.

The preclinical results, presented at the 44th Annual Meeting of the American Society of Cell Biology in Washington, DC, showed that small interfering RNAs (siRNAs), molecules that mediate RNAi, can silence VEGF expression, thereby...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-01-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry